BD PROJECTS
Product for Licensing
On August 7, 2025, Eli Lilly reported its second-quarter financial results, which exceeded…
If interested, please contact DrugTimes BD Team asap! Our email address is: BD@drugtimes.cn
The RAS gene family—comprising KRAS, NRAS, and HRAS—is one of the most frequently mutated …
If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
In recent years, dual- and triple-targeting agents acting on glucagon-like peptide-1 recep…
While numerous anticoagulants with diverse mechanisms of action (e.g., Eliquis, heparin, w…
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, characte…
Geographic Atrophy (GA), a late-stage form of age-related macular degeneration (AMD), has …
In the early clinical development of atopic dermatitis (AD), multiple inflammatory factors…
Growing evidence suggests that inflammatory responses play a pivotal role in the pathogene…
Project ID：DT-202500428-041 Product Brief Summary More highlights Contact us: For any ques…
Project ID：DT-202500410-038 Product Brief Summary More highlights Contact us: For any ques…
Request for Product
Driven by the rising prevalence of eye diseases and increased public awareness of healthca…
Semaglutide, a GLP-1 receptor agonist, can truly be described as a “breakout star…
On July 9, 2025, Novartis struck another deal, acquiring Sironax’s “Brain Deli…
If your company is interested in this opportunity, please contact DrugTimes BD team as soon as possible!
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
Please contact the DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
If your company is interested in this opportunity, please contact us as soon as possible!
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
Bio News
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
For more bio-news, please follow DrugTimes. Many thanks!
We cordially invite you to join us live on May 17 as we work together to accelerate the globalization of China’s innovative drugs. See you online!
For more reports, please follow DrugTimes
Congratulations to Dr. Tie-Ling Wang and VastPro PharmaTech!
DrugTimes will continue to follow up and report in a timely manner
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
DrugTimes Team will keep updating this document in the coming days. All comments are highly welcome!~
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
Congratulations to GSK and Vesalius Therapeutics!
Congratulations to CSPC and AstraZeneca!
Congratulations to Sunshine Lake Pharma and Apollo Therapeutics!
Insights
On August 5, 2025, XtalPi Inc. entered into a collaboration agreement with Dovetree (a com…
Vertex Pharmaceuticals faces renewed setbacks in its non-opioid analgesic pipeline. Its Na…
On August 5, 2025, Robert F. Kennedy Jr., the newly appointed U.S. Secretary of Health and…
On August 1, 2025, local time, Allogene Therapeutics (hereinafter referred to as “Al…
August 2, 2025 – The clinical trial application for SNC115, a DLL3-targeting chimeric anti…
During the Q2 earnings call, when asked whether Moderna was considering M&A deals in C…
On July 17, 2025, a landmark achievement was made in the “world’s first”…
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
In the field of biopharmaceuticals, there is no eternal No. 1, only infinite possibilities
This is an inspiring story of drug development for patients in great need
